AnaptysBio is a clinical-stage biotechnology company developing antibody therapeutics for inflammatory and immune-mediated diseases. Its pipeline has centered on checkpoint agonists and other immuno-modulatory antibodies, with programs aimed at conditions such as atopic dermatitis and rheumatoid arthritis. The company also holds royalty and milestone interests from partnered assets, notably in oncology, which supplement its own clinical development efforts.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 27.8 | — | -39.3 | — |
| Q2 2025 | 22.3 | — | -38.6 | — |
| Q3 2025 | 76.3 | — | 15.1 | — |
| Q4 2025 | 108.3 | — | 49.6 | — |
| Q1 2026 | 25.6 | -8% | -52.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TriMas Corporation (TRS), Corsair Gaming, Inc. (CRSR), National Vision Holdings, Inc. (EYE), Liquidity Services, Inc. (LQDT), Community Trust Bancorp, Inc. (CTBI), Uniti Group Inc. (UNIT)